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Public Health Challenges of Delivering
COVID-19 Vaccines
ANTHONY D. SO, MD, MPA†

Scarcely a day has gone by in recent months when the issue of
Covid-19 vaccine access has not played out in the news. Here we are,
a year into the global pandemic. The number of Covid-19 cases
globally approaches 130 million, and deaths, over 2.8 million. The
grim totals tracked on the Hopkins’ Covid-19 dashboard show that the
United States leads in Covid-19 case counts, with over 30 million
cases, double the 12 plus million cases seen in Brazil and India, each.
In the U.S., the number of deaths now exceeds 550,000, a total greater
than the number of lives lost in World War One, World War Two, and
the Vietnam War combined, and a fifth of the world’s total. A year
later, our focus is on the hope that vaccines might help turn the tide on
this pandemic.
Our Program—the Innovation + Design Enabling Access (IDEA)
Initiative at the Johns Hopkins Bloomberg School of Public Health—
took a snapshot in mid-November of last year as to where reservations
of Covid-19 vaccines stood. The signs of the impending inequities
were beginning to take shape even then. At that time, none of the
Covid-19 vaccines had received emergency use authorization from the
FDA, nor any market approval. Several countries had made pre-market
purchase commitments totaling nearly seven and a half billion doses
or 3.76 billion courses. Just over half of these doses were going into
high income countries, which represented 14% of the world’s
population. Looking at projected production capacity, if all of the
leading vaccine candidates at the time had successfully scaled to the
† Dr. So is Professor of the Practice and Director of the Innovation+Design Enabling
Access (IDEA) Initiative in the Johns Hopkins Bloomberg School of Public Health. Dr. So
acknowledges and thanks his colleague, Joshua Woo, for his contribution in developing and
editing these remarks.
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projected manufacturing capacity, we would have come to nearly 6
billion courses by the end of 2021. Up to about 40% of these vaccine
courses might have potentially remained for low- and middle-income
countries. On a per capita basis, if these vaccine candidates had all
successfully scaled, Canada, followed by Australia, the UK, Japan, the
European Union and the U.S. had all reserved at least one vaccine
course per person within their respective countries, and Canada topped
the list with nearly five reserved COVID-19 vaccine courses per
person.
Contracts between countries and the COVAX facility, which is
the vaccines pillar of the World Health Organization’s efforts to
deliver vaccines, and the vaccine manufacturers were not fully
transparent. We could glean in part details from press releases, the U.S.
Securities and Exchange Commission disclosures, and heavily
redacted Freedom of Information Act requests. As the pandemic
emerged last year, the World Health Organization proposed a global,
equitable allocation approach that would distribute vaccines to reach a
percentage of the world’s population, initially 3%, and then up to 20%
in each country. The priority was to cover health care and essential
workers, as well as vulnerable populations in every country, so that the
backbone of our health care systems could withstand the coming wave
of Covid-19 cases.
In the meantime, over half a dozen Covid-19 vaccines on various
platforms came onto the market, typically under emergency use
authorization. The Covid-19 vaccine market is unlike anything we
have seen for biological products. There are 263 Covid-19 vaccine
candidates in the Research and Development (R&D) pipeline
currently. The delayed ramp up of the COVAX facility allowed
bilateral agreements to proliferate, bypassing this global effort to
supply Covid-19 vaccines. Thus, as the rollout has proceeded, stark
inequities in vaccine administration have emerged. As our recently
published perspective piece of Cell Med reveals, those vaccinated have
reached nearly 300 million doses, 60% in high income countries and
most of the rest in middle-income countries. But these vaccine doses
have gone to very few countries. The U.S. and China alone comprise
over 40% of the total.
Serving as the vaccines pillar of the World Health Organization’s
Access to Covid-19 Tools, or ACT accelerator, the COVAX facility
seeks to bridge some of the gaps in global access to Covid-19 vaccines.
It has taken shape with the stewardship of GAVI, the Vaccine Alliance,
the Coalition for Epidemic Preparedness Innovations, or CEPI, and
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WHO, among other partners. Boosted by recent pledges from G7
countries, the COVAX Facility has mobilized $6.3 billion dollars for
92 lower income countries eligible to receive donor-funded doses of
Covid-19 vaccines. The U.S. under President Biden has joined
COVAX, pledging $4 billion dollars of this total. And as of now,
COVAX secured over their goal of 2 billion doses. However, in the
first two quarters of this year COVAX will roll out about 240 million
doses, 12% of its end-of-the-year goal of 2 billion doses. And as of
April 1st, 2021, the initiative has rolled out only 32 million doses,
leaving most lower income countries considerably short of achieving
herd immunity through vaccination.
Covid-19 vaccine prices vary, not only widely across platforms,
but also somewhat across different buyers. These price differences can
make a huge difference in the rollout of these vaccines, particularly in
countries where the economic downturn has hit hard and healthcare
systems are strapped for resources. Switching from the
AstraZeneca/Oxford vaccine to an mRNA vaccine could result in
requiring a greater level of financing. Even for the same vaccine
candidate, prices vary across the U.S., the European Union and the
COVAX facility. Of note, the E.U. is paying even less for the
AstraZeneca/Oxford vaccine per dose than the COVAX facility is. The
U.S., however, is paying slightly less for the Moderna vaccine, but
footed more than two and a half billion dollars in both push and pull
financing to bring the mRNA vaccine to market.
While several vaccine manufacturers have pledged pandemic
pricing, some reportedly at no profit, the question remains: when will
pandemic pricing go away?
Now, the stark reality is that we are some ways off from supply
meeting demand. So, share-and-exchange mechanisms might be
critical to ensuring vaccines are deployed efficiently and more
equitably across the globe. The landscape of vaccine access continues
to change rapidly. While the vaccine doses may not yet be in hand, all
the G7 countries have secured sufficient approved Covid-19 vaccines
to cover their entire populations. Canada currently remains in the lead
with over 11 doses reserved per person. The US now has close to 10
doses reserved per person, but also has a Covid-19 case burden of more
than 30 million. As population coverage for these countries rises, the
question now is: at what level of domestic vaccination efforts will
national governments be prepared to share available vaccine supplies
with other countries?
Our Program recently suggested a temporal trading of places in
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the queue might also speed global access. For example, should the
United States which has not yet approved the AstraZeneca/ Oxford
vaccine make a temporal trade on its reserved doses with countries
waiting and ready to use this vaccine now? In fact, the United States
has begun to take steps in this direction by pledging some of its early
AstraZeneca/Oxford doses to Canada and Mexico, while this vaccine
still awaits FDA emergency use authorization here in the United
States. We realize that there remains considerable uncertainty around
the duration of immunity, both from infection and from the use of these
vaccines. And we also cannot be sure of how effective all these
vaccines will be against emerging Covid-19 variants, but now is the
time to make clear public and principled commitments at least to share
any surplus and to help mobilize the manufacturing capacity to make
up for the difference for the world. We will only be as secure as the
weakest link in our global vaccination efforts. But a share-andexchange mechanism may face an uphill battle as export restrictions
on Covid-19 vaccines fall into place from Europe to India. They are
disrupting vaccination plans across the globe. Facing under-delivery
of the AstraZeneca/Oxford vaccines destined to the European Union,
Italy recently blocked 250,000 of these vaccine doses to Australia.
Other limits to share-and-exchange mechanisms have to do with
the characteristics of vaccines. Two of the three mRNA vaccines—
Pfizer/BioNTech and Moderna—are already on the market, with very
similar levels of effectiveness. The third mRNA vaccine CureVac is
on its way. A key difference already known across these vaccines is
the cold chain storage requirements. Pfizer/BioNTech requires an
ultra-cold chain and must, for part of its journey and storage, be kept
at minus 70 degrees centigrade. Moderna also requires freezer
temperatures, but only at minus 20 degrees centigrade. The CureVac
vaccine, however, if it proves to be as safe and effective as the other
two, only requires standard refrigerator temperatures and can be stored
at least three months at these temperatures. This difference could be a
critical one in ensuring broader distribution, particularly in low- and
middle-income countries where an ultra-cold chain might be very
difficult and expensive to maintain.
Manufacturing facilities will rapidly become locked up by the
first comers among these mRNA vaccines, however. If the public
sector were to invest more heavily in scale-up of such facilities, would
it be possible to undergo the switching from scaling up the manufacture
of one mRNA vaccine to a better second-generation mRNA vaccine?
This can make a pivotal difference. And as new variants emerge, we
might be better positioned to switch to a superior, second-generation
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vaccine.
As the value of second-generation vaccines becomes more
evident, so will the need to share intellectual property (IP). Just as the
first-generation vaccines have depended on the ability to license a key
patented, publicly funded invention to stabilize the spike protein, so
may be the case for second-generation vaccines. Over 30 of these
vaccines in the pipeline are based on the mRNA vaccine platform, yet
a patent landscape of the mRNA vaccine space found the intellectual
property holdings to be highly fragmented, with BioNTech, Moderna,
CureVac and GSK collectively owning half of these patent
applications. Concerns over the cross licensing of such IP have
prompted proposals, such as the WTO TRIPS waiver, and the Covid19 Technology Access Pool, or CTAP, to emerge. CTAP is a proposal
by Costa Rica backed by 40 member states, calling upon the World
Health Organization to launch a pooling of intellectual property to
accelerate the development of technologies to tackle Covid-19. To
ensure sustainable access to Covid-19 vaccines, particularly to address
Covid-19 variants, we will still face challenges to scale production,
maintain a stable supply until the pandemic subsides, and stockpile for
the next resurgence.
Furthermore, we should not only pool intellectual property to
enable innovation, but also pool procurement. Using monopsony, or
demand-side, power, an intergovernmental facility for pooled
procurement could forecast demand, assure drug manufacturers of
secure payment, and provide technical assistance for scaling up these
products. Fortunately, we have lessons to build upon: the Global Drug
Facility has worked to ensure access to TB commodities. The PAHO
Revolving Fund for Vaccine Access has purchased vaccines for the
Latin American and Caribbean region for years, and UNICEF has done
so globally. Beyond procurement, governments can also exercise
greater control over the manufacture of technologies for Covid-19. The
U.S. government has had the Defense Production Act on the books
since the Korean War. Under this authority, the federal government
can compel manufacturers to produce specific goods from ventilators
to personal protective equipment to combat the pandemic. And the law
has been used regularly to place thousands of orders, particularly by
the military, to prioritize its orders to manufacturers over other clients,
but not much so for COVID-19. However, President Biden announced
in February that he would use the Defense Production Act to scale up
manufacturing of the Moderna and Pfizer/BioNTech vaccines.
Finally, to break the pandemic, we have to lower the rate of
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transmissibility R(t). This goal will only be achievable if effective herd
immunity is reached in the population, population coverage is
sufficiently high, and pandemic social distancing measures hold while
the other two aims are achieved. Herd immunity is reached both by
those becoming vaccinated developing immunity, and by those
infected by Covid-19 manifesting natural immunity. Vaccine
hesitancy, particularly among certain parts of the population, may
prove challenging, and outreach, especially to communities of color in
the United States, will require particular attention. Hopefully, vaccine
hesitancy over time will diminish as public confidence in the vaccine
grows. But as we have seen, the road can be a bumpy one as possible
vaccine adverse reactions emerge and have to be evaluated. The delays
in getting vaccination campaigns moving in low- and middle-income
countries also means that part of the herd immunity may result from
widespread exposure to Covid-19. And we are seeing prevalence rates
suggesting prior infection with Covid-19 in upwards of 50% in the
population of Delhi in a recent serological surveillance survey. Highincome countries have shown just how hard vaccination is to achieve,
even in well-resourced settings. The financing of delivery of vaccines
in countries, from cold chain to administration, must also fall into place
if the last-mile challenges are to be surmounted. As the sprint turns into
a marathon, will financial commitments from multilateral institutions
and development banks hold and sustain financing on the road to
recovery?
Pulling all these factors together, we constructed a triangle of
equitable allocation for Covid-19 vaccines. Equitable allocation is a
function of demonstrating vaccine candidate effectiveness, ensuring
financing for healthcare systems and enabling efficient delivery. As
these vaccines become available, three policy levers might help define
the triangle of equitable allocation: development and production,
procurement, and ultimately healthcare delivery. Development and
production shape the supply side; healthcare delivery, the demand side;
and procurement, demand against available supply. How we
triangulate these factors will determine how well we achieve more
equitable allocation of Covid-19 vaccines. Committing to global
access for Covid-19 vaccines is key to avoiding a resurgence of the
pandemic. As we have pointed out though, agreements between
countries and vaccine manufacturers have undermined a globally
coordinated approach, and the ongoing vaccine rollout highlights longstanding inequities in health. We believe the surest path out of this
pandemic is one towards greater equity, and we hope that these
remarks suggest some of the policy levers that might be used to achieve
this.

